Sign inJoin waitlistJoin the waitlist

Robert Vonderheide

Vice President and Vice Dean for Cancer Programs · University of Pennsylvania Health System

Credentials: · · ·

History

Abramson Cancer Center; John H. Glick MD Abramson Cancer Center's Professor · University of Pennsylvania Health System
Present
Abramson Cancer Center · Perelman School of Medicine at the University of Pennsylvania
Present
Abramson Cancer Center · University of Pennsylvania Health System
Present

Dana-Farber Cancer Institute
1999–2001
Dana-Farber Cancer Institute
1996–1999
Internal Medicine
Massachusetts General Hospital
1993–1994
Harvard Medical School
1989–1993
University of Oxford
1986–1989
University of Notre Dame
1982–1985
Oxford University

Research

Understanding the tumor immune microenvironment (TIME) for effective therapy
Review · Nature Medicine · 2018 · 4,854 citations
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Review · Nature Communications · 2016 · 2,341 citations
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Nature · 2015 · 2,020 citations

Susan Domchek
21 papers
Ben Stanger
20 papers
Carl June
19 papers
Andrew Rech
17 papers · 4 as a resident
Gregory Beatty
16 papers · 7 as a fellow
Lee Richman
15 papers · 1 as a resident
Lynn Schuchter
14 papers
Mark O'Hara
14 papers
Alexander Huang
12 papers · 11 as a fellow
Ran Reshef
12 papers
Angela DeMichele
11 papers
David Bajor
11 papers · 5 as a resident

Grants

Changing the Natural History of Pancreatic Ductal Adenocarcinoma with Cancer Interception Strategies
National Cancer Institute · R01
PI · $658K · University of Pennsylvania
2026–2031
Abramson Cancer Center Support Grant
National Cancer Institute · P30
Contact PI · $90.8M · University of Pennsylvania
1997–2027
Radiation and Checkpoint Blockade for Cancer Immune Therapy
National Cancer Institute · P01
Contact PI · $11.5M · University of Pennsylvania
2017–2024
Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer
National Cancer Institute · R01
Contact PI · $3.6M · University of Pennsylvania
2018–2023

Clinical trials

Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Principal investigator · Completed · Phase 1
Abramson Cancer Center at Penn Medicine
2015–2018
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
Principal investigator · Completed · Phase 1
Inovio Pharmaceuticals
2014–2018
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Principal investigator · Completed · Phase 1
Abramson Cancer Center at Penn Medicine
2012–2013
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Principal investigator · Completed · Phase 1
Abramson Cancer Center at Penn Medicine
2010–2016